Drugs / ESK981
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05988918 | Apr 2024 → Feb 2026 overdue | adenosquamous carcinoma, pancreatic adenocarcinoma, pancreatic endocrine carcinoma, pancreatic neuroendocrine tumor +1 | University of Michigan Rogel Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04159896 | Nov 2019 → Mar 2022 | castration-resistant prostate carcinoma, metastatic carcinoma in the bone, metastatic prostate carcinoma | Barbara Ann Karmanos Cancer Institute | Terminated | Missed primary Stop: Enrollment |
| Phase 2 | NCT03562507 | Apr 2019 → Oct 2022 | renal cell carcinoma | University of Michigan Rogel Cancer Center | Terminated | No outcome recorded |
| Phase 2 | NCT03456804 | Mar 2018 → Mar 2023 | castration-resistant prostate carcinoma, metastatic prostate carcinoma, prostate adenocarcinoma | Barbara Ann Karmanos Cancer Institute | Completed | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ESK981 | “ESK981 is a multi-tyrosine kinase and PIKfyve lipid kinase inhibitor that augments immunotherapeutic responses.” PMID 39503807 ↗ Nov 2024 |
| Action | Inhibit | “ESK981 is a potent tyrosine kinase and PIKfyve lipid kinase inhibitor.” PMID 39227508 ↗ Sep 2024 |
| Route | Oral | “ESK981: 160 mg (4 capsules) PO daily” NCT03562507 ↗ |
| Target | PIKFYVE | “ESK981 is a potent tyrosine kinase and PIKfyve lipid kinase inhibitor.” PMID 39227508 ↗ Sep 2024 |